Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes
Bipolar Disorders · 2024
DOI: 10.1111/bdi.13481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bipolar Disorders, 2024. Verfasst von Nalinoë Kernizan und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Health Sciences and Pharmacy-St. Louis College of Pharmacy, St Louis, Missouri, USA. Hauptthemen laut MEDLINE: Bipolar Disorder, Pregnancy Complications, Antipsychotic Agents, Lamotrigine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Introduction
Untreated bipolar disorder in pregnancy is associated with adverse maternal and neonatal outcomes. Despite advances in clinical management, there is concern among obstetric providers and patients about the safety of pharmacological agents for the treatment of bipolar disorder in pregnancy. Recent studies have shown atypical antipsychotics and lamotrigine to have a favorable safety profile; however, little information is published on lurasidone.
Objectives
The objective of this retrospective chart review was to evaluate pregnancy and neonatal outcomes in obstetric patients with bipolar disorder who are untreated, compared to those treated with lurasidone, other atypical antipsychotics, and lamotrigine at a tertiary teaching institution.
Methods
This retrospective cohort study included neonates whose mothers had a diagnosis of bipolar disorder and were referred to the Maternal & Fetal Care Clinic with two documented visits after January 1, 2014, with delivery by October 31, 2017, within an SSM health‐system hospital.
Results
In this study, women with untreated bipolar disorder (not on any mood stabilizer) in pregnancy had significantly higher rates of premature delivery and low birth weight compared to women on mood stabilizers of lamotrigine, lurasidone, and other atypical antipsychotics. No difference was observed for pregnancy or neonatal outcomes between patients taking any of the mood stabilizers.
Conclusions
This study suggests that the use of lurasidone, other atypical antipsychotics, and lamotrigine have better neonatal outcomes than untreated bipolar disorder in pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Health Sciences and Pharmacy-St. Louis College of Pharmacy, St Louis, Missouri, USA.
- SSM Health St. Mary's Hospital Center, St Louis, Missouri, USA.
- College of Public Health and Social Justice, Saint Louis University, St Louis, Missouri, USA.
- Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology & Women's Health, Saint Louis University, St Louis, Missouri, USA.
- Department of Obstetrics, Gynecology & Women's Health, Saint Louis University, St Louis, Missouri, USA.
ORCID-Profile: Alicia Forinash
Zitieren
APA
Kernizan, N., Forinash, A., Yancey, A., Kruger, S., Chavan, N. R., & Mathews, K. (2024). Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes. Bipolar Disorders. https://doi.org/10.1111/bdi.13481
Vancouver
Kernizan N, Forinash A, Yancey A, Kruger S, Chavan NR, Mathews K. Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes. Bipolar Disorders. 2024. doi:10.1111/bdi.13481
BibTeX
@article{Kernizan2024,
author = {Kernizan, Nalinoë and Forinash, Alicia and Yancey, Abigail and Kruger, Samuel and Chavan, Niraj R and Mathews, Katherine},
title = {Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes},
journal = {Bipolar Disorders},
year = {2024},
doi = {10.1111/bdi.13481}
}
EUVIMED